Healio

Good results seen with sofpironium bromide gel in Japanese patients with hyperhidrosis

Please provide your email address to receive an email when new articles are posted on . Sofpironium bromide gel reduced hyperhidrosis with few adverse events in Japanese patients, according to ...
clinicaladvisor.com

Sofpironium Bromide Improves Primary Hyperhidrosis Severity, Sweat Reduction

Sofpironium bromide in the treatment of primary axillary hyperhidrosis improves Hyperhidrosis Disease Severity Scale scores, reduces gravimetric weight of sweat, and improves Dermatology Life Quality ...
Yahoo Finance

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken ...

BOULDER, Colo., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated ...
Monthly Prescribing Reference

Sofpironium Bromide Gel Promising for Primary Axillary Hyperhidrosis

Sofpironium bromide is a structural analogue of glycopyrrolate, an anticholinergic agent. Positive topline results were announced from 2 identical phase 3 studies evaluating sofpironium bromide in ...
Healio

Sofpironium bromide gel improves primary axillary hyperhidrosis in pediatric patients

Please provide your email address to receive an email when new articles are posted on . Treatment with sofpironium bromide gel reduced the severity of primary axillary hyperhidrosis in a cohort of ...
Business Wire

Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis

BOULDER, Colo.--(BUSINESS WIRE)--Brickell Biotech, Inc. (“Brickell”), a clinical-stage medical dermatology company, today announced positive results of its confirmatory Phase 2b study of sofpironium ...
Business Wire

Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

SAN DIEGO--(BUSINESS WIRE)--Brickell Biotech, Inc. (“Brickell”), a clinical-stage medical dermatology company, today announced that the positive confirmatory Phase 2b study (CL-203) results with ...
Yahoo Finance

Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office

BOULDER, Colo., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated ...
Business Insider

Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary ...

Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment Efficacy assessments showed a clinically meaningful and sustained improvement in sweat severity ...
Nasdaq

Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical

BOULDER, Colo., June 15, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated ...
Benzinga.com

Brickell Biotech Soars On Publication Of Positive Midstage Data For Hyperhidrosis Drug

Colorado-based Brickell, which focuses on developing therapeutics for the treatment of debilitating skin diseases, announced publication in the Journal of the American Academy of Dermatology positive ...
Nasdaq

Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office

Any statements made in this press release relating to future financial, legal, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such ...